Jana Buzkova, Chief Operating Officer, NADMED Ltd.
Jana Buzkova, Chief Operating OfficerNAD+ (a critical coenzyme) is one of the most widespread and biologically most important activators within the plant and animal world,” said Euler-Chelpin, who won the 1929 Nobel Prize for Chemistry jointly with Arthur Harden.

Recent studies have shown that changes in the levels of NAD+ and its related metabolites (NADome) can indicate the performance of the metabolic function. The challenge, however, lies in measuring the level of NADs as they are difficult to extract from biological fluids, preventing accurate quantitation. NADMED has overcome this challenge by accurately measuring all four forms of NAD directly from blood using an innovative non-destructive extraction methodology.

“The technology was invented during an effort to meet the requirements of research on mitochondrial disorders. It became a need when we wanted to monitor the effect of the vitamin B3 supplement on patients´ NAD levels,” says Jana Buzkova, Chief Operating Officer at NADMED.

Liliya Euro, the Chief Scientist at the company, took the challenge at the University of Helsinki and started developing the technology, which was meant mainly for cells or tissues of mice. Eventually, she was able to extract NAD from human blood and tissue.

Leveraging its groundbreaking technology, NADMED provides a tool for clinical trials and research by pharma companies, offering more profound insights into metabolism. The company helps the research community tap into the NAD knowledge at different levels.

NADMED Ltd.: Setting the Standard in NAD Profiling

Companies developing drugs or conducting clinical trials can utilize the knowledge to make decisions for better effectiveness of drugs or higher success rate of the trials.

NADMED currently provides two types of NAD measurement kits in two different variants. It offers Q-NADMED Blood Kit, a quantitative assay kit for NAD+ and NADH in blood. It is an CE marked in-vitro diagnostic medical device applicable in clinical laboratories that measures concentrations of NAD+ and NADH metabolites in human blood. The company also offers another kit (Q-NAD tissue/cells Kit) to measure these metabolites through tissue or cells. For measuring NADP+ and NADPH, NADMED provides Q-NADP Blood Kit, which also comes in another variant for measurement through tissue or cells.

NADMED sets the standard in this field by getting an accurate measurement in the first attempt. It also offers laboratory services to support research and drug development.

The technology was invented during an effort to meet the requirements of research on mitochondrial disorders. It became a need when we wanted to monitor the effect of the vitamin B3 supplement on patients´ NAD levels

Helping the researchers analyze the NADs accurately, NADMED empowers them in their endeavour of developing drugs and conducting clinical trials. In the case of drug development, understanding the impact on basic metabolism is of the essence. NADMED helps drug developers assess the level of NADs as they are tightly involved in energy production, which sequentially is crucial for body´s drug responses. As for clinical trials, NAD levels can potentially be used as a biomarker to assess the individual’s responsiveness to the treatment modality in question. NADMED helps companies identify sub-population of patients who might respond better to the intervention. Such insights can improve the success of the trials due to more accurate patient selection.

Going from strength to strength, NADMED plans to provide glutathione kits as well and is currently involved in developing the kits for the market. The service provides a comprehensive measurement of six analytes from a single sample.